medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2017, Number 5

<< Back Next >>

Rev Invest Clin 2017; 69 (5)

Hyperuricemia on Admission Predicts Short-Term Mortality due to Myocardial Infarction in a Population with High Prevalence of Cardiovascular Risk Factors

Mora-Ramírez M, Estevez-Garcia IO, Irigoyen-Camacho ME, Bojalil R, Gonzalez-Pacheco H, Amezcua-Guerra LM

Language: English
References: 27
Page: 247-253
PDF size: 100.37 Kb.


ABSTRACT

Background: National health surveys have revealed an outstandingly high prevalence of obesity, hypertension, and diabetes in Mexico. Objective: To assess whether serum uric acid levels on admission may predict short-term mortality in patients with ST-segment elevation myocardial infarction in a population with an unusually high prevalence of classic cardiovascular risks. Methods: A total of 795 ST-segment elevation myocardial infarction patients undergoing primary reperfusion therapy were classified as having normouricemia or hyperuricemia according to serum uric acid levels at admission, and the occurrence of mortality and major adverse cardiovascular events during coronary care unit stay was assessed. Results: Patients with hyperuricemia (n = 291; mean age 61.2 ± 11.9 years; 74.8% males) were older, obese, hypertensive, and had a higher Killip class at admission than those with normouricemia (n = 504; mean age 57.6 ± 11.3 years; 88.9% males). Mortality rates were 1.7 and 0.7 cases/100 patients per day of coronary care unit stay in hyperuricemic and normouricemic patients, respectively. Comparatively, no association was observed for the occurrence of major adverse cardiovascular events. After multivariate adjustments, independent predictors for short-term mortality were only Killip class ≥ 2 (HR: 13.15; 95% CI: 5.29-29.85; p ‹ 0.0001) and elevated serum uric acid levels (HR: 1.99; 95% CI: 1.08-3.66; p = 0.026). Conclusions: Hyperuricemia on admission remains associated with short-term mortality in ST-segment elevation myocardial infarction patients from a population with an unusually high prevalence of cardiovascular risk factors.


REFERENCES

  1. Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009; 15(Suppl):S36-41.

  2. Gutiérrez J, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Salud Publica Mex. 2012;196.

  3. Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, Rivera-Dommarco JA. [Prevalence of obesity in Mexican adults 2000-2012]. Salud Publica Mex. 2013;55(Suppl 2): S151-60.

  4. Campos-Nonato I, Hernández-Barrera L, Rojas-Martínez R, Pedroza A, Medina-García C, Barquera-Cervera S. [Hypertension: prevalence, early diagnosis, control and trends in Mexican adults]. Salud Publica Mex. 2013;55(Suppl 2):S144-50.

  5. Jiménez-Corona A, Aguilar-Salinas CA, Rojas-Martínez R, Hernández- Ávila M. [Type 2 diabetes and frequency of prevention and control measures]. Salud Publica Mex. 2013;55(Suppl 2): S137-43.

  6. López-Molina R, Parra-Cabrera S, López-Ridaura R, González- Villalpando ME, Ferrannini E, González-Villalpando C. Sweetened beverages intake, hyperuricemia and metabolic syndrome: the Mexico City Diabetes Study. Salud Publica Mex. 2013;55: 557-63.

  7. WHO. Global Health Risks: Mortality and burden of disease attributable to selected major risks. Bull World Health Organ. 2009;87:646.

  8. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications. J Cardiol. 2012;59:235-42.

  9. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13.

  10. Lazzeri C, Valente S, Chiostri M, Sori A, Bernardo P, Gensini GF. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol. 2010;138:206-9.

  11. Ndrepepa G, Braun S, Haase H-U, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012;109:1260-5.

  12. Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109: 486-91.

  13. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. J Am Coll Cardiol. 2001;38:2114-30.

  14. Williams DO, Abbott JD, Kip KE; DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover Registry. Circulation. 2006;114:2154-62.

  15. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63: 3136-41.

  16. Stocker R, Keaney JF. New insights on oxidative stress in the artery wall. J Thromb Haemost. 2005;3:1825-34.

  17. Alcaino H, Greig D, Chiong M, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail. 2008;10:646-51.

  18. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5:265-72.

  19. Godber BL, Doel JJ, Sapkota GP, et al. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem. 2000;275:7757-63.

  20. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: From urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002;9:161-75.

  21. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study. Arthritis Res Ther. 2011; 13:R66.

  22. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011;13:160-6.

  23. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.

  24. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009;11:444-52.

  25. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160:487-92.

  26. Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF. Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern Emerg Med. 2012;7:33-9.

  27. Kojima S, Sakamoto T, Ishihara M, et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (The Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96:489-95.




2020     |     www.medigraphic.com